?:authorAffiliation
|
-
[\'P95 Epidemiology & Pharmacovigilance, Leuven, Belgium. Electronic address: marc.baay@p-95.com.\', \'University Claude Bernard Lyon, VirPath Research Laboratory, Lyon, France. Electronic address: bruno.lina@univ-lyon1.fr.\', \'Department of Global Health, Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr.\', \'Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: arnaud.marchant@ulb.be.\', \'Vaccine R&D, CEPI Vaccines, London, UK. Electronic address: melanie.saville@cepi.net.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: philippe.sabot@iabs.org.\', \'ADVAC, University of Geneva, Geneva, Switzerland. Electronic address: Philippe.Duclos@unige.ch.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: joris.vandeputte@iabs.org.\', \'International Alliance for Biological Standardization - IABS, Geneva, Switzerland. Electronic address: Pieter.neels@vaccine-advice.be.\']
|